"Designing Growth Strategies is in our DNA"
The global diabetes drugs market size was valued at USD 48,753.1 Million in 2018, is projected to reach USD 78,261.7 Million by the end of 2026, exhibiting a CAGR of 6.1%.
Diabetes drugs are the medications which are used to treat diabetes mellitus type 1 and type 2 by lowering the blood glucose level of the body. There are different classes of drugs involved in the treatment of diabetes which are administered via oral route or intravenous and subcutaneous routes. Growing prevalence of diabetes, especially type 2 diabetes, and the increasing demand for effective drug therapies for the treatment of diabetes are some of the factors anticipated to upsurge the diabetes drugs market during the forecast period.
According to the Diabetic statistics report published by the Centers for Disease Control and Prevention (CDC) in 2017, around 30.3 million people in the U.S. were suffering from diabetes among which 23.1 million people were diagnosed with diabetes and the remaining were still undiagnosed. Rise in obesity, growing adoption of a sedentary lifestyle and an increase in the consumption of unhealthy diet are likely to enhance the prevalence of diabetes which are expected to boost the market during the forecast period.
Request a Free sample to learn more about this report.
"Accessibility of low-priced Insulinsupported by growing investments in R&D is likely to boost the growth of insulin segment in the global diabetes drugs market"
Launch of generic versions of insulin and extensively growing demand for novel insulin in controlling the blood sugar levels in both type 1 and type 2 diabetes are factors anticipated to fuel the growth of insulin segment in the market during the forecast period. In March 2019, Eli Lilly and Company launched Lispro, a generic version of rapid-acting Humalog insulin which shall be available in the United States for half the list price of Humalog, making it more accessible for diabetic patients.
Additionally, growing investments in research and development by many government organizations and new product launches by many key players are likely to boost the diabetes drugs market growth during the forecast period. For instance, in 2019 Glenmark launched an oral anti-diabetic drug Remogliflozin in India which is considered as an effective drug in treating adults with type-2 diabetes mellitus.
To know how our report can help streamline your business, Speak to Analyst
On the basis of drug class, the market is categorized into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors and others. In terms of diabetes type, the global market is segmented into diabetes type 1 and diabetes type 2. Further in terms of the route of administration, the market is segmented into oral, subcutaneous and intravenous. On basis of end user, the global market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
"Growing Investments in R&D and Increasing Prevalence of Diabetes Enables Market to Hold Considerable Share in North America"
North America Diabetes Drugs Market, 2018
To get more information on the regional analysis of this market, Request a Free sample
North America generated a diabetes drugs market revenue of US$ 23,965.5 Mn in 2018 and is expected to dominate the market throughout the forecast period. Growing investments in research and development activities by many government organizations and an increase in the prevalence of diabetes are some of the factors anticipated to account for the considerable diabetes drugs market share in North America. Moreover, growing awareness about the novel anti-diabetic drugs, new launches of anti-diabetic drugs, and favorable reimbursement policies are likely to boost the diabetic drugs market in North America. Europe is anticipated to be the second most prominent region in terms of revenue by 2026.
"Novo Nordisk A/S, Eli Lilly and Company and Sanofi Accounts for More Than Half of the Market Share in Terms of Revenue"
Novo Nordisk A/S is a leading player in the diabetes drugs industry. Novo Nordisk A/S is estimated to retain its position during the forecast duration owing to the increasing partnerships which will boost technological innovations, growing investments in research activities to develop a portfolio of superior treatment solutions and developing strategic plans with an aim to provide cost-effective anti-diabetic drugs to the low resource countries. This company along with Sanofi, Eli Lilly and Company currently holds over half of the diabetes drugs market share in terms of revenue. Other players operating in the global market are Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Merck & Co., Inc., and others.
Diabetes drugs are used for the treatment of diabetes mellitus. Insulin is safe as well as easier to administer and are more effective in maintaining the glucose level in patients with diabetes. The rapidly growing prevalence of diabetes and unmet demand in emerging nations are some of the factors anticipated to drive the diabetes drugs market growth by 2026.
The report provides qualitative and quantitative insights on the diabetes drugs industry and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by drug class, by diabetes type, by route of administration, by distribution channel, and by region. On the basis of the drug class, the market is segmented into Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and others.
Diabetes type is segmented into type-1 and type-2 diabetes and the route of administration is segmented into oral, subcutaneous and intravenous. In the report, Online pharmacies, hospital pharmacies, and retail pharmacies are covered under the distribution channel segment. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.
To gain extensive insights into the market, Request for Customization
To gain extensive insights into the market, Request for Customization
Along with this, the report provides elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of diabetes in key countries, introduction of new drugs/approvals by major key players, pipeline analysis, recent industry developments such as mergers, partnerships & acquisitions and the overview of regulatory scenario of key countries/regions.
By Drug Class
· DPP-4 Inhibitors
· GLP-1 Receptor Agonists
· SGLT2 Inhibitors
By Diabetes Type
· Type 1
· Type 2
By Route of Administration
By Distribution Channel
· Online pharmacies
· Hospital Pharmacies
· Retail Pharmacies
· North America (U.S. and Canada)
· Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
· Latin America (Brazil, Mexico, and Rest of Latin America)
· Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)
Fortune Business Insights says that the value of the global Diabetes Drugs Market was USD 48,753.1 Million in 2018.
The Diabetes Drugs Market is projected to reach USD 78,261.7 Million by 2026.
The Diabetes Drugs Market will grow at the rate of 6.1% CAGR.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry